Cargando…

The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias

Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of...

Descripción completa

Detalles Bibliográficos
Autores principales: Masetti, Riccardo, Serravalle, Salvatore, Biagi, Carlotta, Pession, Andrea
Formato: Texto
Lenguaje:English
Publicado: Hindawi Publishing Corporation 2011
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026992/
https://www.ncbi.nlm.nih.gov/pubmed/21318168
http://dx.doi.org/10.1155/2011/148046
_version_ 1782197110680059904
author Masetti, Riccardo
Serravalle, Salvatore
Biagi, Carlotta
Pession, Andrea
author_facet Masetti, Riccardo
Serravalle, Salvatore
Biagi, Carlotta
Pession, Andrea
author_sort Masetti, Riccardo
collection PubMed
description Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia.
format Text
id pubmed-3026992
institution National Center for Biotechnology Information
language English
publishDate 2011
publisher Hindawi Publishing Corporation
record_format MEDLINE/PubMed
spelling pubmed-30269922011-02-11 The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias Masetti, Riccardo Serravalle, Salvatore Biagi, Carlotta Pession, Andrea J Biomed Biotechnol Review Article Acute leukemia is the most common type of childhood and adolescence cancer, characterized by clonal proliferation of variably differentiated myeloid or lymphoid precursors. Recent insights into the molecular pathogenesis of leukemia have shown that epigenetic modifications, such as deacetylation of histones and DNA methylation, play crucial roles in leukemogenesis, by transcriptional silencing of critical genes. Histone deacetylases (HDACs) are potential targets in the treatment of leukaemia, and, as a consequence, inhibitors of HDACs (HDIs) are being studied for therapeutic purposes. HDIs promote or enhance several different anticancer mechanisms, such as apoptosis, cell cycle arrest, and cellular differentiation and, therefore, are in evidence as promising treatment for children and adolescents with acute leukemia, in monotherapy or in association with other anticancer drugs. Here we review the main preclinical and clinical studies regarding the use of HDIs in treating childhood and adolescence leukemia. Hindawi Publishing Corporation 2011 2011-01-13 /pmc/articles/PMC3026992/ /pubmed/21318168 http://dx.doi.org/10.1155/2011/148046 Text en Copyright © 2011 Riccardo Masetti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Review Article
Masetti, Riccardo
Serravalle, Salvatore
Biagi, Carlotta
Pession, Andrea
The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title_full The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title_fullStr The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title_full_unstemmed The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title_short The Role of HDACs Inhibitors in Childhood and Adolescence Acute Leukemias
title_sort role of hdacs inhibitors in childhood and adolescence acute leukemias
topic Review Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3026992/
https://www.ncbi.nlm.nih.gov/pubmed/21318168
http://dx.doi.org/10.1155/2011/148046
work_keys_str_mv AT masettiriccardo theroleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT serravallesalvatore theroleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT biagicarlotta theroleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT pessionandrea theroleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT masettiriccardo roleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT serravallesalvatore roleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT biagicarlotta roleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias
AT pessionandrea roleofhdacsinhibitorsinchildhoodandadolescenceacuteleukemias